Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation

Canadian Journal of Cardiology

Volumn 25, Issue 4, 2009, Pages

  Efremidis, Michalis ^a   Alexanian, Ionnis P ^a   Oikonomou, Dimitrios ^a   Manolatos, Dimitrios ^a   Letsas, Konstantinos P ^a   Pappas, Loukas K ^a   Gavrielatos, Gerasimos ^a   Vadiaka, Maria ^a   Mihas, Constantinos C ^a   Filippatos, Gerasimos S ^b   Sideris, Antonios ^a   Kardaras, Fotios ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atrial fibrillation; Internal cardioversion; Outcome; Prediction; Recurrence

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PROPAFENONE;

ADULT; ARTICLE; CARDIOVERSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEFIBRILLATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART CATHETER; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECURRENT DISEASE; SINUS RHYTHM; SYMPTOM; AGED; CHRONIC DISEASE; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART FUNCTION TEST; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; ROC CURVE; STATISTICAL MODEL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; ATRIAL FIBRILLATION; CHRONIC DISEASE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; ROC CURVE;

EID: 65349163305     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70070-4     Document Type: Article

References (34)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. The Framingham study. N Engl J Med 1982;306:1018-22.
2. Levy S. Internal defibrillation: Where we have been and where we should be going? J Interv Card Electrophysiol 2005;13(Suppl 1):61-6.
3. Wallet C, Callies F, Langenfeld H. Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes. Is external cardioversion contraindicated in patients with permanent pacing systems? Europace 2004;6:165-8.
4. Boriani G, Biffi M, Camanini C, Luceri RM, Branzi A. Transvenous low energy internal cardioversion for atrial fibrillation: A review of clinical applications and future developments. Pacing Clin Electrophysiol 2001;24:99-107.
5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745. (Erratum in 2007;9:856).
6. Corley SD, Epstein AE, DiMarco, JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1509-13.
7. Hagens VE, Ranchor AV, Van SE, et al; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2004;43:241-7.
8. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
9. Sherman DO, Kim SO, Boop BS, et al; National Heart, Lung, and Blood institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005;165:1185-91.
10. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
11. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-80.
12. Torp-Pedersen C, Moler M, Bloch-Thomseri PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
13. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofecilide in the treatment of atrial fibrillation-flutter in patients with'reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-6.
14. Levy S, Ricard P, Lau CP, et al. Multicenter low-energy transvenous atrial defibrillation (XAD) trial results in different subset of atrial fibrillation. J Am Coll Cardiol 1997;29:750-5.
15. Levy S, Ricard P, Gueunoun M, et al. Low-energy cardioversion of spontaneous atrial fibrillation. Immediate and long-term results. Circulation 1997;96:253-9.
16. Taramasco V, Socas A, Ricard P, Levy S. Internal low-energy cardioversion: A therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion. Europace 1999;1:179-82.
17. Lau CP, Lok NS. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol 1997;20:2442-52.
18. Boriani G, Biffi M, Bronzetti G, et al. Efficacy and tolerability in fully conscious patients of transvenous low energy internal atrial cardioversion for atrial fibrillation. Am J Cardiol 1998;81:241-4.
19. Alt E, Schmitt C, Ammer R, et al. Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation. Am J Cardiol 1997;79:621-5.
20. Boriani G, Biffi M, Pergolini F, Zannoli R, Branzi A, Magnani B. Low-energy internal atrial cardioversion in atrial fibrillation lasting more than a year. Pacing Clin Electrophysiol 1999;22:243-6.
21. Schmitt C, Alt E, Plewan A, et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996;28:994-9.
22. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation induced electrical remodelling of the atria? J Am Coll Cardiol 1998;31:167-73.
23. Manios EG, Kanoupakis EM, Chlouverakis GI, Kaleboubas MD, Mavrakis HE, Vardas PE. Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: Relation with recurrence. Cardiovasc Res 2000;47:244-53.
24. Bollmann A, Hussser D, Steinert R, et al. Echocardiographic and electrocardiographic predictors for AF recurrence following cardioversion. J Cardiovasc Electrophysiol 2003;14:S162-5.
25. Olshansky B, Heller EN, Brent L, et al. Are transthoracic. echocardiographic parameters associated with atrial fibrillation recurrence or stroke? J Am Coll Cardiol 2005;45:2026-33.
26. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 1995;76:355-8.
27. Spiecker M, Bohm S, Borgel J, et al. Doppler echocardiographic prediction of recurrent atrial fibrillation following cardioversion. Int J Cardiol 2006;113:161-6.
28. Tieleman RG, Blaauw Y, Van Gelder IC. Digoxin delays recovery from tachycardia induced electrical remodeling of the atria. Circulation 1999; 100: 1836-42.
29. Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000;102:2503-8.
30. Coumel P, Attuel P, Lavallee J. The atrial arrhythmia syndrome of vagal origin. Arch Mat Coeur Vaiss 1978;71:645-56.
31. Tieleman RG, De Langen C, Van Gelder IC, et al. Veraparnil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997;95:1945,53.
32. Biffi M, Boriani G, Bartolotti M, Bacchi Reggiani L, Zannoli R, Branzi A. Atrial fibrillation recurrence after internal cardioversion: Prognostic importance of electrophysiological parameters. Heart 2002;87;443-8.
33. Rait M, Kusumoto W, Giraud G, McAnulty J. Electrophysiologic predictors of the recurrence of persistent atrial fibrillation within 30 days of cardioversion. Am J Cardiol 2004;93:107-10.
34. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res 2002;54:230-46.